Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.99 USD | -0.50% | -3.37% | -82.80% |
May. 09 | EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 04 | Health Care Down on Retreat From Risk -- Health Care Roundup | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 9.41M |
---|---|---|---|---|---|
Net income 2024 * | -34M | Net income 2025 * | -37M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18M | Net cash position 2025 * | 51M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.32
x | P/E ratio 2025 * |
-0.89
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.91% |
Latest transcript on eFFECTOR Therapeutics, Inc.
1 day | -0.50% | ||
1 week | -3.37% | ||
Current month | -10.67% | ||
1 month | +4.15% | ||
3 months | -82.76% | ||
6 months | -86.26% | ||
Current year | -82.80% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 12-04-30 |
Michael Byrnes
DFI | Director of Finance/CFO | 47 | 20-11-30 |
Douglas Warner
CTO | Chief Tech/Sci/R&D Officer | 52 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 12-04-30 |
Director/Board Member | 54 | 21-08-24 | |
Caroline Loewy
BRD | Director/Board Member | 58 | 23-09-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 2.01 | +0.50% | 10 663 |
24-05-14 | 2 | 0.00% | 133,625 |
24-05-13 | 2 | -1.48% | 108,205 |
24-05-10 | 2.03 | -5.14% | 85,411 |
24-05-09 | 2.14 | +2.88% | 120,545 |
Delayed Quote Nasdaq, May 15, 2024 at 09:56 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.80% | 9.41M | |
+5.92% | 111B | |
+11.69% | 106B | |
-12.67% | 22.24B | |
+0.06% | 21.25B | |
-4.83% | 18.97B | |
-35.21% | 18.52B | |
-10.55% | 16.81B | |
+37.76% | 12.54B | |
-24.71% | 8.09B |
- Stock Market
- Equities
- EFTR Stock